NEW YORK, Feb. 7, 2017 /PRNewswire/ -- Noble Capital
Markets announced today that it has initiated research coverage on
Anavex Life Sciences Corp. (Nasdaq: AVXL) The report was issued by
Noble's Head of Biotechnology Research, Kumar Raja, PhD.
Anavex Life Sciences is a biopharmaceutical company developing
innovative therapies for neurological disorders and cancer. The
company uses its SIGMACEPTOR ™ Discovery Platform to develop novel
drugs that target neurological and neurodegenerative diseases, such
as Alzheimer's, Parkinsons's, Rett Syndrome and different forms of
cancers.
The lead product candidate, ANAVEX 2-73, is on path for a Phase
2/3 in Alzheimer's disease and a Phase 2 study in Rett's Syndrome.
In previous trials, ANAVEX 2-73 has exhibited a high affinity and
selection to sigma-1 receptors, and has shown synergistic action
with other receptors, such as Muscarinic and N-methyl-D-aspartate
(NMDA) in clinical trials. The drug has also displayed a favorable
side effect profile, which can be beneficial to patients and
advantageous when compared to current treatments.
The full report and disclosures can be accessed by clicking
here
For further information please contact Steve Rashkin at 561-994-5738 or
srashkin@noblecapitalmarkets.com
About Noble Capital Markets
(www.noblecapitalmarkets.com)
Noble Capital Markets established in 1984, is an equity-research
driven, full-service, investment & merchant banking boutique
focused on the healthcare, media & entertainment, technology
and natural resources sectors. The company has offices in
Boca Raton (HQ), New York and Boston. In addition to the annual multi-sector
NobleCon, each year Noble hosts numerous "non-deal" corporate road
shows and sector-specific conferences such as the Media, Finance
& Investor Conference offered in partnership with the National
Association of Broadcasters (NAB).
Members: FINRA, SIPC, MSRB
This publication is intended for information purposes only and
shall not constitute an offer to buy/sell or the solicitation of an
offer to buy/sell any security mentioned in this report, nor shall
there be any sale of the security herein in any state or domicile
in which said offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or domicile. This publication and all information,
comments, statements or opinions contained or expressed herein are
applicable only as of the date of this publication and subject to
change without prior notice. Past performance is not indicative of
future results.
Please see disclosure, valuation methods, price charts, and
ratings histories available in the complete research report,
available by clicking here or
contacting Noble Capital Markets at 561-994-5738. The
securities covered by or mentioned in the reports involve
substantial risk and should generally be purchased only by
investors able to accept such risk.
Related Links: www.noblecapitalmarkets.com
Noble Capital Markets is a member of
the Financial Industry Regulatory Authority, CRD number
15768.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/noble-capital-markets-initiates-research-coverage-on-anavex-life-sciences-corp-avxl-300403268.html
SOURCE Noble Capital Markets